COMMUNIQUÉS West-GlobeNewswire
-
TRUE-See Selected to Participate in Microsoft for Start-Ups Azure AI Program to Accelerate Innovation and Growth
25/06/2026 -
Nanox Announces First Quarter 2026 Financial Results and Provides Business Updates
25/06/2026 -
Lycia Therapeutics Raises $75 Million in Oversubscribed Financing and Strengthens Leadership Team with Appointment of Chief Financial Officer and General Counsel
25/06/2026 -
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
25/06/2026 -
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
25/06/2026 -
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
25/06/2026 -
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management
25/06/2026 -
AnaCardio´s Phase 1b/2a GOAL-HF1 study in patients with Heart Failure and Reduced Ejection Fraction (HFrEF) published in The Lancet
25/06/2026 -
Herantis appoints experienced drug development expert Dr Juha Savola as Chief Medical Officer
25/06/2026 -
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
25/06/2026 -
EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
25/06/2026 -
Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL‑051 for Autoimmune Diseases into Clinical Development
25/06/2026 -
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
25/06/2026 -
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
25/06/2026 -
Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development
25/06/2026 -
BrewDog Inverurie Reopens with New Community Champions Model
25/06/2026 -
Young workers willing to make career trade-offs for jobs with pensions: new research from HOOPP and Abacus Data
25/06/2026 -
Un nouveau projet de l’ACE pour soutenir les ergothérapeutes diplômés à l’étranger au Canada
25/06/2026 -
AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets
25/06/2026
Pages